N-(2-pyridinemethylene)-2-pyridinamine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: N-(2-pyridinemethylene)-2-pyridinamine
• 英文别名: N-(2-Pyrimidinylmethylene)-2-pyridinamine；(E)-N,1-dipyridin-2-ylmethanimine
• 化学式: C₁₁H₉N₃
• 分子量: 183.213
• InChiKey: MPPSKYJIXTWGRP-NTEUORMPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  38.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-(2-pyridinemethylene)-2-pyridinamine 、 亚磷酸二乙酯 以40%的产率得到
  参考文献：
  名称：

  Failla Salvatore, Finocchiaro Paolo, Latronico Mario, Libertini Manuela, Phosph., Sulfur and Silicon and Relat. Elem, 88 (1994) N 1-4, S 185-188

  摘要：

  DOI：
• 作为产物：
  描述：

  吡啶-2-甲醛 、 2-氨基吡啶 在 对甲苯磺酸 作用下， 以 甲苯 为溶剂， 生成 N-(2-pyridinemethylene)-2-pyridinamine
  参考文献：
  名称：

  Molecular structure of di-aryl-aldimines by multinuclear magnetic resonance and X-ray diffraction

  摘要：

  The complete H-1, C-13 and N-15 NMR analyses for a series of 25 diaryl-aldimines containing phenyl, pyridyl, pyrazolone and furanyl moieties are described herein. Detailed evaluation of substituent chemical shift and coupling constant effects showed that interaction between the lone pair of the pyrazolone carbonyl group or the nitrogen of 2-substitued pyridines with the aldimine hydrogen increases the (1)J(CH) value and shifts the resonance signal for this hydrogen to high frequency, in the H-1 NMR spectra. The X-ray crystal structure analysis of pyrazolone substituted aldimines evidenced the planarity of the aryl groups which are conjugated with the C=N double bond. In the case of the N-(2-pyridinemethylene)-1,5-dimethyl-2-phenyl-1,2-dihydro-pyrazol-3-one, two rotamers were observed in the same unit cell. (C) 2003 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/s0022-2860(03)00279-5

文献信息

• LIGHT INDUCED DRUG RELEASE
  申请人：Bonnet Sylvestre

  公开号：US20140148425A1

  公开（公告）日：2014-05-29

  Photosensitive compounds for use in a method of treating a disease or condition are described. The photosensitive compounds have the formula R—Y, wherein R is a ruthenium complex and Y is at least one sulphur-containing photoreleasable group, and the compounds comprise at least one ruthenium-sulphur bond; or a pharmaceutically acceptable salt, solvate, ester or amide, such that upon influence of visible or near infra-red light (400-1400 nm) in vivo, said at least one ruthenium-sulphur bond is broken, thereby generating a pharmacologically active compound.

  描述了用于治疗疾病或症状的一种方法中使用的光敏化合物。这些光敏化合物具有R—Y的化学式，其中R是一个钌配合物，Y是至少一个含硫光释放基团，这些化合物包括至少一个钌-硫键；或者是药用可接受的盐、溶剂合物、酯或酰胺，因此，在体内受到可见光或近红外光（400-1400纳米）的影响时，所述至少一个钌-硫键被断裂，从而产生一种药理活性化合物。
• REACTION OF COMPOUNDS WITH A H-P BOND WITH SCHIFF-BASES
  作者：Jian Rohovec、Pavel Vojtíšek、Ivan Lukeš

  DOI：10.1080/10426509908037002

  日期：1999.5.1

  with a P-H bond to Schiff bases of both simple and macrocyclic compounds proceeds smoothly as a non catalysed thermally initialised reaction in an inert solvent. For macrocyclic systems and bulky phosphorus substituents a stereoselective formation of the trans isomer was confirmed by X ray analysis. The addition is reversible, and the reverse reaction is catalysed by Lewis acids. The trans orientation

  摘要 具有 PH 键的化合物与简单和大环化合物的席夫碱的加成作为惰性溶剂中的非催化热初始化反应顺利进行。对于大环系统和庞大的磷取代基，通过 X 射线分析证实了反式异构体的立体选择性形成。加成是可逆的，逆反应由路易斯酸催化。大环上磷取代基的反式取向、分子的立体化学刚性和加成的可逆性限制了以这种方式形成的化合物作为配体的用途。
• Photoactivatable cancer prodrug
  申请人：Texas State University

  公开号：US10781226B2

  公开（公告）日：2020-09-22

  Described herein is photocaging methodology using ruthenium (II) complexes with 7-deazahypoxanthine-based anticancer agents. Specifically, 7-deazahypoxanthines are converted into photoactivatable chemotherapeutic agents for the controlled release of these toxic agents selectively into tumor tissue upon irradiation with light.

  本文描述的是利用钌 (II) 复合物与 7-脱氮次黄嘌呤类抗癌剂的光致癌方法。具体来说，就是将 7-脱氮次黄嘌呤转化为可光活化的化疗药物，以便在光照射下将这些有毒药物有选择性地控制释放到肿瘤组织中。
• EL-SHAFEL, A. K.;HASSAN, KH. M., CURR. SCI., INDIA, 1983, 52, N 13, 633-634
  作者：EL-SHAFEL, A. K.、HASSAN, KH. M.

  DOI：——

  日期：——
• PHOTOACTIVATABLE CANCER PRODRUG
  申请人：Texas State University

  公开号：US20200239503A1

  公开（公告）日：2020-07-30

  Described herein is photocaging methodology using ruthenium (II) complexes with 7-deazahypoxanthine-based anticancer agents. Specifically, 7-deazahypoxanthines are converted into photoactivatable chemotherapeutic agents for the controlled release of these toxic agents selectively into tumor tissue upon irradiation with light.